Search

Your search keyword '"Al-Zoairy, Ramona"' showing total 19 results
Start Over Author "Al-Zoairy, Ramona"
19 results on '"Al-Zoairy, Ramona"'

6. Hepatitis C virus eradication with direct‐acting antiviral improves insulin resistance

Author

Russo, Francesco Paolo, primary, Zanetto, Alberto, additional, Gambato, Martina, additional, Bortoluzzi, Ilaria, additional, Al Zoairy, Ramona, additional, Franceschet, Enrica, additional, De Marchi, Federica, additional, Marzi, Luca, additional, Lynch, Erica Nicola, additional, Floreani, Annarosa, additional, Farinati, Fabio, additional, Schaefer, Benedikt, additional, Burra, Patrizia, additional, Zoller, Heinz, additional, and Mega, Andrea, additional

Published
2019
Full Text
View/download PDF

7. Management of patients with chronic hepatitis C failing repeated courses of interferon‐free direct acting antiviral combination therapy

Author

Kozbial, Karin, primary, Al‐Zoairy, Ramona, additional, Gschwantler, Michael, additional, Stauber, Rudolf, additional, Hametner, Stephanie, additional, Laferl, Hermann, additional, Strasser, Michael, additional, Hayat‐Khayyati, Avida, additional, Datz, Christian, additional, Kramer, Ludwig, additional, Schaefer, Benedikt, additional, Maieron, Andreas, additional, Graziadei, Ivo, additional, Stättermayer, Albert Friedrich, additional, Beinhardt, Sandra, additional, Munda, Petra, additional, Zoller, Heinz, additional, Holzmann, Heidemarie, additional, Aberle, Stephan W., additional, Trauner, Michael, additional, Hofer, Harald, additional, and Ferenci, Peter, additional

Published
2019
Full Text
View/download PDF

8. Hepatitis C virus eradication with direct‐acting antiviral improves insulin resistance.

Author

Russo, Francesco Paolo, Zanetto, Alberto, Gambato, Martina, Bortoluzzi, Ilaria, Al Zoairy, Ramona, Franceschet, Enrica, De Marchi, Federica, Marzi, Luca, Lynch, Erica Nicola, Floreani, Annarosa, Farinati, Fabio, Schaefer, Benedikt, Burra, Patrizia, Zoller, Heinz, and Mega, Andrea

Subjects
HEPATITIS C virus, ANTIVIRAL agents, INSULIN resistance, CIRRHOSIS of the liver, DIABETES
Abstract

Sustained virological response (SVR) after interferon‐based therapy is associated with improvement of insulin resistance (IR) in HCV‐infected patients. Few data are available in the direct‐acting antivirals (DAAs) era, especially in cirrhotic patients. We prospectively evaluated the long‐term effect of DAAs on IR. Patients treated with DAAs between May 2015 and December 2016 in 3 tertiary care centres were recruited. Patients with diabetes were excluded. Biochemical and virological data were collected at baseline, 12/24/48 weeks (W) after the end of therapy (EOT). Presence of IR was defined by a 'homeostasis model assessment index for IR' [HOMA‐IR])> 2.5. Liver fibroscan was performed at baseline, at 24/48W after EOT. Hundred and thirty‐eight patients were enrolled (mean age 58 years, M/F 85/53, GT1 61%, 68.8% cirrhotic). Sixty‐eight patients (94/138) had IR. Patients with IR had significantly higher stiffness than patients without it (23 ± 12 vs 15 ± 8; P <.0001). SVR12 was achieved in 135 (98%) patients, and 124 (90%) patients reached the 48W post‐EOT. At this time point, the percentage of patients with IR significantly decreased to 49% (P = 0,01). HOMA‐IR was significantly lower than baseline (1.8 vs 3; P <.001), and this was related to a significant reduction of insulin level (11.7 ± 6.3 vs 16.4 ± 8.3). High BMI was associated with a significantly lower probability of achieving a non‐IR status at 24W (P =.05) and 48W (P =.03).In conclusion, SVR following DAAs led to a significant reduction of IR, even in patients with cirrhosis. Nevertheless, IR can persist after the achievement of SVR, especially in patients with high BMI. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

9. Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030

Author

Schaefer, Benedikt, primary, Viveiros, André, additional, Al-Zoairy, Ramona, additional, Blach, Sarah, additional, Brandon, Samantha, additional, Razavi, Homie, additional, Dorn, Livia, additional, Finkenstedt, Armin, additional, Effenberger, Maria, additional, Graziadei, Ivo, additional, Sarcletti, Mario, additional, Tilg, Herbert, additional, and Zoller, Heinz, additional

Published
2018
Full Text
View/download PDF

10. Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation

Author

Beinhardt, Sandra, primary, Al-Zoairy, Ramona, additional, Kozbial, Karin, additional, Stättermayer, Albert F., additional, Maieron, Andreas, additional, Stauber, Rudolf, additional, Strasser, Michael, additional, Zoller, Heinz, additional, Graziadei, Ivo, additional, Rasoul-Rockenschaub, Susanne, additional, Trauner, Michael, additional, Ferenci, Peter, additional, and Hofer, Harald, additional

Published
2018
Full Text
View/download PDF

11. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment

Author

Kozbial, Karin, primary, Moser, Stephan, additional, Al-Zoairy, Ramona, additional, Schwarzer, Remy, additional, Datz, Christian, additional, Stauber, Rudolf, additional, Laferl, Hermann, additional, Strasser, Michael, additional, Beinhardt, Sandra, additional, Stättermayer, Albert F., additional, Gschwantler, Michael, additional, Zoller, Heinz, additional, Maieron, Andreas, additional, Graziadei, Ivo, additional, Trauner, Michael, additional, Steindl-Munda, Petra, additional, Hofer, Harald, additional, and Ferenci, Peter, additional

Published
2017
Full Text
View/download PDF

12. Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C

Author

Rudolf E. Stauber, Asia Karpi, Wolfgang Vogel, Heinz Zoller, Ivo Graziadei, C Freissmuth, Al-Zoairy Ramona, R Stern, S Hametner, Andreas Maieron, Peter Ferenci, Michael Gschwantler, S Moser, Harald Hofer, Karin Kozbial, and Hermann Laferl

Subjects
Simeprevir, Male, Pyrrolidines, Sofosbuvir, Sustained Virologic Response, viruses, Treatment outcome, Antiviral Agents, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Chronic hepatitis, Interferon, Recurrence, Sleep Initiation and Maintenance Disorders, Medicine, Humans, 030212 general & internal medicine, Antiviral treatment, Fatigue, Aged, Aged, 80 and over, Fluorenes, Hepatology, business.industry, Ribavirin, Pruritus, Gastroenterology, Imidazoles, virus diseases, Valine, biochemical phenomena, metabolism, and nutrition, Hepatitis C, Chronic, Virology, digestive system diseases, Treatment Outcome, chemistry, 030211 gastroenterology & hepatology, Benzimidazoles, Drug Therapy, Combination, Female, Carbamates, business, medicine.drug
Abstract

Interferon/Ribavirin-Free Antiviral Treatment in Septuagenarians and Octogenarians With Chronic Hepatitis C

Published
2016

14. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment

Author

Kozbial, Karin, primary, Moser, Stephan, additional, Schwarzer, Remy, additional, Laferl, Hermann, additional, Al-Zoairy, Ramona, additional, Stauber, Rudolf, additional, Stättermayer, Albert F., additional, Beinhardt, Sandra, additional, Graziadei, Ivo, additional, Freissmuth, Clarissa, additional, Maieron, Andreas, additional, Gschwantler, Michael, additional, Strasser, Michael, additional, Peck-Radosalvjevic, Markus, additional, Trauner, Michael, additional, Hofer, Harald, additional, and Ferenci, Peter, additional

Published
2016
Full Text
View/download PDF

15. DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting

Author

Beinhardt, Sandra, primary, Al Zoairy, Ramona, additional, Ferenci, Peter, additional, Kozbial, Karin, additional, Freissmuth, Clarissa, additional, Stern, Rafael, additional, Stättermayer, Albert Friedrich, additional, Stauber, Rudolf, additional, Strasser, Michael, additional, Zoller, Heinz, additional, Watschinger, Bruno, additional, Schmidt, Alice, additional, Trauner, Michael, additional, Hofer, Harald, additional, and Maieron, Andreas, additional

Published
2016
Full Text
View/download PDF

16. Follow‐up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin‐free treatment.

Author

Kozbial, Karin, Moser, Stephan, Al‐Zoairy, Ramona, Schwarzer, Remy, Datz, Christian, Stauber, Rudolf, Laferl, Hermann, Strasser, Michael, Beinhardt, Sandra, Stättermayer, Albert F., Gschwantler, Michael, Zoller, Heinz, Maieron, Andreas, Graziadei, Ivo, Trauner, Michael, Steindl‐Munda, Petra, Hofer, Harald, and Ferenci, Peter

Subjects
ANTIVIRAL agents, CIRRHOSIS of the liver, LIVER cancer, LIVER transplantation, FIBROSIS
Abstract

Abstract: Background: The introduction of direct‐acting antivirals (DAA) has increased sustained virological response (SVR) rates in patients with advanced liver disease and chronic hepatitis C(CHC)infection. At present, data on clinical outcome and long‐term durability of viral eradication after successful DAA therapy are scarce. Aim: To evaluate the long‐term success of viral eradication in patients with advanced fibrosis or cirrhosis treated with DAAs. Methods: Five hundred and fifty‐one patients with advanced fibrosis (n = 158) or cirrhosis (CPS‐A:317,CPS‐B/C:76) and SVR after interferon and ribavirin‐free DAA therapy treated between October 2013 and April 2016 were studied with a median follow‐up of 65.6 (13.0‐155.3) weeks. Only patients without hepatocellular carcinoma (HCC) at baseline and without liver transplantation were included. Results: Twelve patients (2.2%) died during follow‐up: the mortality rate was 0.6% in F3, 2.2% in CPS‐A and 5.3% in CPS‐B/C patients (P = .08). During follow‐up 36 patients with cirrhosis (9.1%) developed a liver related event, including 16 with de‐novo HCC (4.1%). Seven patients were transplanted at a median of 9.7 (range 3.8‐21.7) months after EOT. History of decompensation was significantly associated with liver related events during follow‐up (HR 7.9; 95% CI 2.7‐22.6; P < .001), and with mortality (HR 5.5; 95% CI 1.5‐20.2, P = .01). Conclusions: Eradication of HCV by DAA therapy was durable irrespective of the DAA combination used. Most of the cured patients had an excellent long‐term clinical prognosis. Nevertheless, the risk of new occurrence of HCC remains worrisome and thus regular surveillance is obligatory even after clinical stabilization and improvement of the patient. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

18. Quantitative analysis of volatile organic compounds released and consumed by rat L6 skeletal muscle cells in vitro

Author

Mochalski, Paweł, Al-Zoairy, Ramona, Niederwanger, Andreas, Unterkofler, Karl, and Amann, Anton

Subjects
Male, Muscle Cells, Volatile Organic Compounds, Time Factors, Reproducibility of Results, release of VOCs, Article, Gas Chromatography-Mass Spectrometry, Cell Line, Rats, uptake of VOCs, Exhalation, Limit of Detection, enzyme expression, Animals, Humans, skeletal muscle, L6 cells, Muscle, Skeletal
Abstract

Knowledge of the release of volatile organic compounds (VOCs) by cells provides important information on the origin of VOCs in exhaled breath. Muscle cells are particularly important, since their release of volatiles during the exertion of an effort contributes considerably to breath concentration profiles. Presently, the cultivation of human skeletal muscle cells is encountering a number of obstacles, necessitating the use of animal muscle cells in in vitro studies. Rat L6 skeletal muscle cells are therefore commonly used as a model for studying the molecular mechanisms of human skeletal muscle differentiation and functions, and facilitate the study of the origin and metabolic fate of the endogenously produced compounds observed in breath and skin emanations. Within this study the production and uptake of VOCs by rat L6 skeletal muscle cells were investigated using gas chromatography with mass spectrometric detection, combined with head-space needle trap extraction as the pre-concentration technique (HS-NTE-GC-MS). Seven compounds were found to be produced, whereas sixteen species were consumed (Wilcoxon signed-rank test, p < 0.05) by the cells being studied. The set of released volatiles included two ketones (2-pentanone and 2-nonanone), two volatile sulphur compounds (dimethyl sulfide and methyl 5-methyl-2-furyl sulphide), and three hydrocarbons (2-methyl 1-propene, n-pentane and isoprene). Of the metabolized species there were thirteen aldehydes (2-propenal, 2-methyl 2-propenal, 2-methyl propanal, 2-butenal, 2-methyl butanal, 3-methyl butanal, n-pentanal, 2-methyl 2-butenal, n-hexanal, benzaldehyde, n-octanal, n-nonanal and n-decanal), two esters (n-propyl propionate and n-butyl acetate), and one volatile sulphur compound (dimethyl disulfide). The possible metabolic pathways leading to the uptake and release of these compounds by L6 cells are proposed and discussed. An analysis of the VOCs showed them to have huge potential for the identification and monitoring of some molecular mechanism and conditions.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results